Clinical Trial Update: Pharmacokinetic Study of Iron Isomaltoside 1000 Administered by 250 mg IV Bolus Injection or 500 mg Intravenous Infusion to Patients With Non-hematological Malignancies Associated With Chemotherapy Induced Anaemia [Phase 1]

View source ↗

Summary

Phase 1 pharmacokinetic study evaluating iron isomaltoside 1000 administered as a 250 mg IV bolus or a 500 mg intravenous infusion in patients with chemotherapy…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cancer
• Chemotherapy-induced Anemia

Drugs mentioned

• Iron isomaltoside 1000 (iron isomaltoside 1000)

Snippet

Sponsor: Pharmacosmos A/S | Conditions: Patients With Chemotherapy Induced Anemia (CIA) | Phase 1 | Status: COMPLETED